Research output per year
Research output per year
Description
These files comprise the supplementary data for Pope et al. (2024) "Ultra-sensitive detection of circulating tumour DNA enriches for patients with greater risk of recurrence in clinically localised prostate cancer"
Supplementary Table 1 (in 1-s2.0-S0302283824000034-mmc1.docx) describes the clinical characteristics of the participants in the paper, combining 41 samples from Australia and 77 samples from the UK.
Supplementary Table 2 (in 1-s2.0-S0302283824000034-mmc2.xlsx) describes the 128 healthy male controls used in the paper, and the analysis batches for which they were used.
Supplementary Table 3 (in 1-s2.0-S0302283824000034-mmc1.docx) describes the 17 analysis batches studied in the paper.
Supplementary Table 4 (in 1-s2.0-S0302283824000034-mmc3.xlsx) details the key sequencing statistics, including the number of targets (by batch and by patient), the sequencing coverage achieved, and the proportion of targets covered for different thresholds.
Supplementary Table 5 (in 1-s2.0-S0302283824000034-mmc4.xlsx) details for 118 patients their key demographic, clinical and molecular characteristics, as well as whether circulating tumour DNA was detected.
Supplementary Table 6 (1-s2.0-S0302283824000034-mmc5.docx) Further details of cases where circulating tumour DNA was detected
Supplementary Table 7 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives the outcome of an analysis of time to biochemical recurrence modelled in terms of PSA, pathologist T stage, ISUP grade group and whether ctDNA was detected.
Supplementary Table 8 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives the outcome of an analysis of time to metastasis modelled in terms of PSA, pathologist T stage, ISUP grade group and whether ctDNA was detected.
Supplementary Table 9 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives a summary of all survival models (both outcomes and whether adjusted for covariates or not).
Supplementary Table X (1-s2.0-S0302283824000034-mmc6.xlsx) Details of the members of the author collaboration "The Pan Prostate Cancer Group (PPCG)"
Supplementary Table 1 (in 1-s2.0-S0302283824000034-mmc1.docx) describes the clinical characteristics of the participants in the paper, combining 41 samples from Australia and 77 samples from the UK.
Supplementary Table 2 (in 1-s2.0-S0302283824000034-mmc2.xlsx) describes the 128 healthy male controls used in the paper, and the analysis batches for which they were used.
Supplementary Table 3 (in 1-s2.0-S0302283824000034-mmc1.docx) describes the 17 analysis batches studied in the paper.
Supplementary Table 4 (in 1-s2.0-S0302283824000034-mmc3.xlsx) details the key sequencing statistics, including the number of targets (by batch and by patient), the sequencing coverage achieved, and the proportion of targets covered for different thresholds.
Supplementary Table 5 (in 1-s2.0-S0302283824000034-mmc4.xlsx) details for 118 patients their key demographic, clinical and molecular characteristics, as well as whether circulating tumour DNA was detected.
Supplementary Table 6 (1-s2.0-S0302283824000034-mmc5.docx) Further details of cases where circulating tumour DNA was detected
Supplementary Table 7 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives the outcome of an analysis of time to biochemical recurrence modelled in terms of PSA, pathologist T stage, ISUP grade group and whether ctDNA was detected.
Supplementary Table 8 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives the outcome of an analysis of time to metastasis modelled in terms of PSA, pathologist T stage, ISUP grade group and whether ctDNA was detected.
Supplementary Table 9 (in 1-s2.0-S0302283824000034-mmc1.docx) Gives a summary of all survival models (both outcomes and whether adjusted for covariates or not).
Supplementary Table X (1-s2.0-S0302283824000034-mmc6.xlsx) Details of the members of the author collaboration "The Pan Prostate Cancer Group (PPCG)"
| Date made available | 13 Jan 2025 |
|---|---|
| Publisher | University of St Andrews |
Research output
- 1 Letter
-
Ultra-sensitive detection of circulating tumour DNA enriches for patients with greater risk of recurrence in clinically localised prostate cancer
Pope, B., Park, G., Lau, E., Belic, J., Lach, R., George, A., McCoy, P., Nguyen, A., Grima, C., Campbell, B., Jung, C.-H., Ditter, E.-J., Zhao, H., Wedge, D., Brewer, D., Lynch, A., Dev, H., Gnanpragasam, V., Rosenfeld, N. & Hovens, C. & 3 others, , 1 Apr 2024, In: European Urology. 85, 4, p. 407-410 4 p.Research output: Contribution to journal › Letter › peer-review
Open AccessFile